Fig. 5: MA10 SARS-CoV-2 challenge of BALB/c mice immunized with RhAd52.CoV.Consv vaccine. | npj Vaccines

Fig. 5: MA10 SARS-CoV-2 challenge of BALB/c mice immunized with RhAd52.CoV.Consv vaccine.

From: Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex

Fig. 5

a Challenge study plan. Groups of BALB/c mice were immunized with different prime/boost regimens of RhAd52.S.PP and CoV.Consv vaccines at week 0 (prime) and week 4 (boost), bled at week 6, and challenged with 104 PFU of mouse-adapted MA10 SARS-CoV-2 at week 8 post-prime. Mouse serum was analyzed for spike-specific binding antibody titers (b) and neutralizing antibody titers (c) using an ELISA or a pseudovirus neutralization assay, respectively. d, e Longitudinal weight loss (d) and maximum weight loss (e) were observed over 4 days post-challenge (Groups 2 and 3 were made dashed to improve viewer clarity). f, g Lung PFU titers (f), and Nasal Turbinate PFU titers (g) were measured at day 4 post-challenge for each challenge group. Longitudinal weight loss shown as mean ± the SEM for each prime / boost vaccine group. Individual mice in (b, c, e–g) denoted as dots with group median values depicted as a black line. Red dotted lines depict assay limit of detection (b, c, f, g). P values represent two sided Mann–Whitney tests (f, g).

Back to article page